Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Drug patents and clinical trials in dozens of countries
  • Set up watchlists for daily email updates

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

How our clients use DrugPatentWatch

DrugPatentWatch Database Preview

Ethinyl estradiol - Generic Drug Details

« Back to Dashboard

What are the generic drug sources, and freedom to operate, for ethinyl estradiol?

Ethinyl estradiol is the generic ingredient in one hundred and ninety-three branded drugs marketed by Pharmacia And Upjohn, Organon Usa Inc, Schering, Mylan Labs Ltd, Watson Labs, Mayne Pharma, Gd Searle Llc, Barr, Parke Davis, Sandoz, Vintage Pharms Llc, Labs Leon Farma, Lupin Ltd, Amneal Pharms, Duramed Pharms Barr, Novast Labs Ltd, Teva Branded Pharm, Glenmark Generics, Bayer Hlthcare, Glenmark Pharms Ltd, Wyeth Pharms Inc, Aurobindo Pharma Ltd, Wyeth Pharms, Sandoz Inc, Mylan Technologies, Janssen Pharms, Ortho Mcneil Pharm, Vintage Pharms, Warner Chilcott Llc, Warner Chilcott, LPI, Allergan Sales Llc, Ortho Mcneil Janssen, Apil, Barr Labs Inc, Lupin Atlantis, Lupin Pharms, Glenmark Pharms, Haupt Pharma, Oc Pharma, and Pelagius, and is included in two hundred and forty-three NDAs. There are sixteen patents protecting this compound. Additional information is available in the individual branded drug profile pages.

There are twenty-six drug master file entries for ethinyl estradiol. There is one tentative approval for this compound.

Summary for Generic Name: ethinyl estradiol

Drug Master File Entries: see list26
Bulk Api Vendors: see list47
Clinical Trials: see list261
Patent Applications: see list11,758
Therapeutic Class:Hormonal Agents, Stimulant/Replacement/Modifying (Sex Hormones/Modifiers)
Formulation / Manufacturing:see details
Drug Prices:see low prices
DailyMed Link:ethinyl estradiol at DailyMed

Tentative approvals for ETHINYL ESTRADIOL

Applicant Application No. Form Dosage
► Subscribe► SubscribeTABLET;ORAL0.03MG,0.01MG; 0.15MG,N/A
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Mylan Technologies
ethinyl estradiol; norelgestromin
FILM, EXTENDED RELEASE;TRANSDERMAL200910-001Apr 16, 2014RXNoYes► Subscribe► Subscribe
JUNEL 1.5/30
ethinyl estradiol; norethindrone acetate
TABLET;ORAL-21076381-001May 30, 2003RXNoNo► Subscribe► Subscribe
Amneal Pharms
ethinyl estradiol; levonorgestrel
TABLET;ORAL-28201108-001Feb 5, 2014RXNoNo► Subscribe► Subscribe
Parke Davis
NORLESTRIN 21 2.5/50
ethinyl estradiol; norethindrone acetate
TABLET;ORAL-21016852-001Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe
Sandoz Inc
ethinyl estradiol; levonorgestrel
TABLET;ORAL-28201088-001May 21, 2015RXNoNo► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How our clients use DrugPatentWatch

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.